Clarus Wealth Advisors Blueprint Medicines Corp Transaction History
Clarus Wealth Advisors
- $200 Million
- Q4 2024
A detailed history of Clarus Wealth Advisors transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Clarus Wealth Advisors holds 2,573 shares of BPMC stock, worth $223,053. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,573
Previous 2,590
0.66%
Holding current value
$223,053
Previous $239,000
6.28%
% of portfolio
0.11%
Previous 0.12%
Shares
5 transactions
Others Institutions Holding BPMC
# of Institutions
380Shares Held
65.9MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$587 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$576 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$492 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$371 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$217 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.18B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...